New fund launches €100m
Enlarge image


New fund launches €100m

28.02.2013 - Belgian Gimv launches a new Healthcare and Medtech fund to invest in the European health and care sectors.

The European investment company, which manages investments of 1.8bn in 85 portfolio companies, will initially invest €50m in the new fund. The Flemish Government will also contribute €50m through Gimv's reference shareholder, VPM. The fund is seeking to attract additional investments from institutional investors.

A formal first closing is planned in the coming year, said the investment company.Over the next six years, the fund aims to invest in 10 to 15 healthcare and medtech companies in the Benelux, Germany and France. The amount per investment can peak to €25m, both in equity and quasi-equity. With a term of 12 years, the fund presents itself as a long-term partner for the projects in which it will invest. The Gimv Health & Care team will be responsible for the management of the fund.

”The ageing population, a rising number of chronic diseases and better informed patients continue to push up healthcare demand and costs“ commented Urbain Vandeurzen, Chairman of the Gimv Board of Directors ”With the new fund, we want to encourage innovative companies and service providers in the sector to respond to this."

The Health & Care fund is not Gimv's first project in this field. The Flemish Government's venture capital fund for biotech companies, Biotech Fonds Vlaanderen, is managed by Gimv. Gimv is also responsible for the management of two infrastructure funds (DG Infra+ and DG Infra Yield). In early 2009, Gimv established the Gimv-XL fund for investments in larger Flemish growth companies. Later that year, the Gimv-Agri+ Investment Fund was launched in cooperation with the famers' league Boerenbond. Lastly, in 2011, the Gimv Arkiv Tech Fund II was set up as part of the second ARKimedes arrangement.



12.10.2015 Aberdeen University spinout TauRx has picked up US$135m from a VC financing round. The biopharma company plans to bring its dementia hopeful through Phase III trials.


09.10.2015 The US pricing controversy is reverberating halfway across the globe. Shield Therapeutics has taken its IPO plans off the table. Market conditions are too volatile, the company says.


07.10.2015 T-cell specialist Adaptimmune Therapeutics plc needs more space for its R&D in immuno-oncology. The expanding UK company is building a major facility that will house 200 staff.

Drug DiscoveryGermany

06.10.2015 Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.

Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • ZELTIA (E)4.12 EUR22.99%
  • PHARMING (NL)0.32 EUR10.34%
  • PLETHORA (UK)3.12 GBP8.33%


  • THERAMETRICS (CH)0.03 CHF-25.00%
  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • OREXO (S)65.00 SEK40.4%
  • ZEALAND PHARMA (DK)160.00 DKK31.1%
  • THROMBOGENICS (B)3.98 EUR30.1%


  • THERAMETRICS (CH)0.03 CHF-50.0%
  • GALAPAGOS (B)38.68 EUR-25.8%


  • KARO BIO (S)41.90 SEK5137.5%
  • CHRONTECH PHARMA (S)0.34 SEK466.7%
  • GALAPAGOS (B)38.68 EUR247.8%


  • NEOVACS (F)0.75 EUR-76.1%
  • BIOTEST (D)19.54 EUR-72.9%
  • EVOCUTIS (UK)0.15 GBP-68.7%

No liability assumed, Date: 12.10.2015